Non-severe aplastic anemia
Conditions
Interventions
Jili Shengxue Formula combined with stanozolol treatment group:Combined treatment with Jili Shengxue Formula and stanozolol
Sponsors
Zhejiang Provincial Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
3 Years to 88 Years
Inclusion criteria
Inclusion criteria: 1 Meets the diagnostic criteria for NSAA as specified in the Chinese Guidelines for the Diagnosis and Treatment of Aplastic Anemia (2022);? 2 Has received combined treatment with Jili Shengxue Formula and stanozolol for = 3 months;? 3 Has complete medical records and follow-up dat
Exclusion criteria
Exclusion criteria: 1 Congenital or hereditary aplastic anemia (e.g., Fanconi anemia, telomere disorders) or hereditary bone marrow failure syndrome with definite evidence;? 2 Complicated with other hematological diseases, including myelodysplastic syndrome (MDS), paroxysmal nocturnal hemoglobinuria (PNH) in clinically overt phase, and leukemia;? 3 Previous history of hematopoietic stem cell transplantation (HSCT);? 4 Complicated with severe infection, active tuberculosis, or other severe systemic diseases;? 5 Incomplete medical records or patients deemed unsuitable for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate (ORR);Complete Remission Rate (CR);Partial Remission Rate (PR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin Improvement Level;Platelet improvement degree;Absolute Neutrophil Count Improvement Degree;Blood Transfusion-Dependent Outcome;Functional Assessment of Cancer Therapy-Anemia Scale Score;Adverse reaction incidence rate; | — |
Countries
China
Contacts
Public ContactWuDijing
Zhejiang Provincial Hospital of Traditional Chinese Medicine
Outcome results
None listed